VRCA · Verrica Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| PERCEPTIVE ADVISORS LLC Director | ▲ Buy | Open Market | 7,099,182 Shares held | 12/29/2023 | View profile |
| Paul B. Manning Director | ▲ Buy | Open Market | 3,348,372 Shares held | 11/25/2025 | View profile |
| John A. Stalfort III Director | ▼ Sell | Gift | 1,873,800 Shares held | 11/26/2024 | View profile |
| Ted White President and CEO | ▼ Sell | Open Market | 215,967 Shares held | 8/27/2024 | View profile |
| Jayson Rieger CEO and President | ▲ Buy | Open Market | 207,593 Shares held | 8/17/2026 | View profile |
| Christopher G. Hayes Chief Legal Officer | ▼ Sell | Open Market | 176,458 Shares held | 3/17/2025 | View profile |
| Gary Goldenberg Chief Medical Officer | ▼ Sell | Open Market | 94,261 Shares held | 8/27/2024 | View profile |
| Joe Bonaccorso Chief Commercial Officer | ▼ Sell | Open Market | 73,114 Shares held | 8/27/2024 | View profile |
| Terry Kohler CFO and Treasurer | ▼ Sell | Open Market | 44,697 Shares held | 8/27/2024 | View profile |
| David Zawitz Chief Operating Officer | ▲ Buy | Open Market | 27,000 Shares held | 8/17/2026 | View profile |
| John J. Kirby Interim CFO | ▲ Buy | Open Market | 23,962 Shares held | 8/18/2026 | View profile |
| Noah L. Rosenberg CMO | ▲ Buy | Open Market | 8,587 Shares held | 8/18/2026 | View profile |
Transaction History
| Noah L. Rosenberg | ▲ Buy | Open Market | 2,030 | $10K | 8/18/2026 |
| John J. Kirby | ▲ Buy | Open Market | 5,000 | $25K | 8/18/2026 |
| David Zawitz | ▲ Buy | Open Market | 6,000 | $30K | 8/17/2026 |
| Jayson Rieger | ▲ Buy | Open Market | 5,000 | $25K | 8/17/2026 |
| Noah L. Rosenberg | ▲ Buy | Open Market | 4,200 | $21K | 8/17/2026 |
| Jayson Rieger | ▲ Buy | Open Market | 20,000 | $101K | 8/14/2026 |
| John J. Kirby | ▲ Buy | Grant | 10,000 | $0 | 12/23/2025 |
| Jayson Rieger | ▲ Buy | Open Market | 94,311 | $400K | 11/25/2025 |
| Paul B. Manning | ▲ Buy | Open Market | 1,375,380 | $5.8M | 11/25/2025 |
| Paul B. Manning | ▲ Buy | Open Market | 2,750,762 | $11.7M | 11/25/2025 |
| Noah L. Rosenberg | ▲ Buy | Open Market | 2,357 | $10K | 11/25/2025 |
| John J. Kirby | ▲ Buy | Open Market | 3,536 | $15K | 11/25/2025 |
| David Zawitz | ▲ Buy | Open Market | 10,000 | $42K | 11/25/2025 |
| Christopher G. Hayes | ▼ Sell | Open Market | 4,315 | $3K | 3/17/2025 |
| Jayson Rieger | ▼ Sell | Gift | 50,000 | $0 | 11/26/2024 |
| John A. Stalfort III | ▼ Sell | Gift | 50,000 | $0 | 11/26/2024 |
| Paul B. Manning | ▼ Sell | Gift | 450,000 | $0 | 11/26/2024 |
| Jayson Rieger | ▲ Buy | Open Market | 280,898 | — | 11/22/2024 |
| John A. Stalfort III | ▲ Buy | Open Market | 1,123,595 | — | 11/22/2024 |
| Paul B. Manning | ▲ Buy | Open Market | 18,426,966 | — | 11/22/2024 |
| Paul B. Manning | ▲ Buy | Open Market | 4,494,382 | — | 11/22/2024 |
| John J. Kirby | ▲ Buy | Grant | 54,267 | $0 | 11/6/2024 |
| Paul B. Manning | ▼ Sell | Gift | 2,675,611 | $0 | 9/19/2024 |
| Paul B. Manning | ▼ Sell | Gift | 891,870 | $0 | 9/19/2024 |
| Paul B. Manning | ▼ Sell | Gift | 891,870 | $0 | 9/19/2024 |
| Paul B. Manning | ▼ Sell | Gift | 891,870 | $0 | 9/19/2024 |
| Terry Kohler | ▼ Sell | Open Market | 7,899 | $19K | 8/27/2024 |
| Christopher G. Hayes | ▼ Sell | Open Market | 9,530 | $23K | 8/27/2024 |
| Ted White | ▼ Sell | Open Market | 9,021 | $22K | 8/27/2024 |
| Gary Goldenberg | ▼ Sell | Open Market | 3,601 | $9K | 8/27/2024 |
| Joe Bonaccorso | ▼ Sell | Open Market | 8,993 | $22K | 8/27/2024 |
| Ted White | ▼ Sell | Open Market | 24,979 | $66K | 8/26/2024 |
| Gary Goldenberg | ▼ Sell | Open Market | 9,888 | $26K | 8/26/2024 |
| Joe Bonaccorso | ▼ Sell | Open Market | 24,709 | $66K | 8/26/2024 |
| Terry Kohler | ▼ Sell | Open Market | 21,820 | $58K | 8/26/2024 |
| Christopher G. Hayes | ▼ Sell | Open Market | 26,183 | $70K | 8/26/2024 |
| Ted White | ▼ Sell | Open Market | 154 | $1K | 7/23/2024 |
| Joe Bonaccorso | ▼ Sell | Open Market | 115 | $803 | 7/23/2024 |
| Gary Goldenberg | ▼ Sell | Open Market | 86 | $600 | 7/23/2024 |
| Christopher G. Hayes | ▼ Sell | Open Market | 91 | $635 | 7/23/2024 |
| Ted White | ▼ Sell | Open Market | 32,469 | $229K | 7/22/2024 |
| Joe Bonaccorso | ▼ Sell | Open Market | 25,461 | $180K | 7/22/2024 |
| Gary Goldenberg | ▼ Sell | Open Market | 18,421 | $130K | 7/22/2024 |
| Christopher G. Hayes | ▼ Sell | Open Market | 21,649 | $153K | 7/22/2024 |
| Gary Goldenberg | ▲ Buy | Grant | 40,000 | $0 | 3/15/2024 |
| Ted White | ▲ Buy | Grant | 112,500 | $0 | 3/15/2024 |
| Joe Bonaccorso | ▲ Buy | Grant | 40,000 | $0 | 3/15/2024 |
| Terry Kohler | ▲ Buy | Grant | 40,000 | $0 | 3/15/2024 |
| Christopher G. Hayes | ▲ Buy | Grant | 40,000 | $0 | 3/15/2024 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 115,774 | $838K | 12/29/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 126,116 | $893K | 12/28/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 79,726 | $574K | 12/27/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 54,652 | $355K | 12/26/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 250,000 | $1.7M | 12/22/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 200,000 | $1.2M | 12/21/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 277,008 | $1.5M | 12/19/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 456,923 | $2.5M | 12/18/2023 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 500,000 | $3.0M | 12/15/2023 |
| Joe Bonaccorso | ▼ Sell | Open Market | 11,266 | $33K | 11/15/2023 |
| Terry Kohler | ▼ Sell | Open Market | 9,632 | $29K | 11/15/2023 |
| Gary Goldenberg | ▼ Sell | Open Market | 3,036 | $9K | 11/15/2023 |
| Ted White | ▼ Sell | Open Market | 11,558 | $34K | 11/15/2023 |
| Christopher G. Hayes | ▼ Sell | Open Market | 11,558 | $34K | 11/15/2023 |
| Gary Goldenberg | ▼ Sell | Open Market | 5,817 | $17K | 11/14/2023 |
| Terry Kohler | ▼ Sell | Open Market | 18,452 | $54K | 11/14/2023 |
| Ted White | ▼ Sell | Open Market | 22,141 | $65K | 11/14/2023 |
| Joe Bonaccorso | ▼ Sell | Open Market | 21,580 | $63K | 11/14/2023 |
| Christopher G. Hayes | ▼ Sell | Open Market | 22,141 | $65K | 11/14/2023 |
| Terry Kohler | ▲ Buy | Grant | 62,500 | $0 | 8/24/2023 |
| Ted White | ▲ Buy | Grant | 75,000 | $0 | 8/24/2023 |
| Christopher G. Hayes | ▲ Buy | Grant | 75,000 | $0 | 8/24/2023 |
| Gary Goldenberg | ▲ Buy | Grant | 25,000 | $0 | 8/24/2023 |
| Joe Bonaccorso | ▲ Buy | Grant | 62,500 | $0 | 8/24/2023 |
| Christopher G. Hayes | ▼ Sell | Open Market | 33,789 | $163K | 7/24/2023 |
| Gary Goldenberg | ▼ Sell | Open Market | 28,699 | $139K | 7/24/2023 |
| Joe Bonaccorso | ▼ Sell | Open Market | 38,262 | $185K | 7/24/2023 |
| Ted White | ▼ Sell | Open Market | 50,677 | $245K | 7/24/2023 |
| Paul B. Manning | ▲ Buy | Open Market | 200,000 | $1.0M | 7/24/2023 |
| Christopher G. Hayes | ▲ Buy | Grant | 100,000 | $0 | 7/21/2023 |
| Gary Goldenberg | ▲ Buy | Grant | 75,000 | $0 | 7/21/2023 |
| Joe Bonaccorso | ▲ Buy | Grant | 100,000 | $0 | 7/21/2023 |
| Ted White | ▲ Buy | Grant | 150,000 | $0 | 7/21/2023 |
| Christopher G. Hayes | ▲ Buy | Open Market | 7,500 | $26K | 7/11/2022 |
| Ted White | ▲ Buy | Open Market | 23,809 | $50K | 7/5/2022 |
| Gary Goldenberg | ▲ Buy | Open Market | 23,809 | $50K | 7/5/2022 |
| John A. Stalfort III | ▲ Buy | Open Market | 238,095 | $500K | 7/5/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 4,761,904 | $10.0M | 7/5/2022 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 1,428,571 | $3.0M | 7/5/2022 |
| Christopher G. Hayes | ▲ Buy | Open Market | 5,714 | $12K | 7/5/2022 |
| Paul B. Manning | ▲ Buy | Open Market | 19,977 | $184K | 12/3/2021 |
| Paul B. Manning | ▲ Buy | Open Market | 30,023 | $284K | 12/2/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Verrica to present new YCANTH data at dermatology conferences
Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.
Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.